In this study, administration of a TGF‐β receptor inhibitor (LY364947) once daily for 3 days dispersed the CD8+ T cells from CAF high‐density regions throughout the tumor tissue without reducing α‐SMA, a CAF cell marker, in LLC1 tumor masses (Figure S7). This evidence concerns the gene CD8A and neoplasm.